Stelara® Alternatives

Stelara is an immunosuppressant medication that targets two inflammatory cytokines, IL-12 and IL-23, which are key contributors to chronic inflammation. For Crohn's disease and ulcerative colitis, Stelara is administered every 8 weeks, and for psoriasis, it is given every 12 weeks. Its most frequently reported side effects are an increased susceptibility to infection, as well as nasopharyngitis, headache, and fatigue.

Stelara is FDA approved for the following indications: Plaque Psoriasis, Psoriatic Arthritis, Crohn’s Disease, and Ulcerative Colitis.

Taltz, a monoclonal antibody, has anti-inflammatory properties and can potentially alleviate symptoms of psoriasis, psoriatic arthritis, or ankylosing spondylitis. Its administration involves subcutaneous injection, and the most common side effects include injection site reactions and an elevated susceptibility to infections.

Taltz is FDA approved for the following indications: Plaque Psoriasis, Psoriatic Arthritis, Ankylosing Spondylitis, and Non-Radiographic Axial Spondylarthritis.